Last reviewed · How we verify
Noradrenaline
At a glance
| Generic name | Noradrenaline |
|---|---|
| Also known as | early noradrenaline infusion, Norepinephrine, ATC-code C01CA03 |
| Sponsor | Tanta University |
| Target | Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Alpha-1D adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Approved indications
- Acute exacerbation of asthma
- Asthma
- Asthma management
- Bronchiectasis
- Bronchitis
- Low blood pressure
- Pulmonary emphysema
Common side effects
Key clinical trials
- Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction (PHASE4)
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Diagnosis of Pheochromocytoma (PHASE1)
- The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster (NA)
- Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial) (NA)
- Comparing Two Different Norepinephrine Infusion Rates for Prophylaxis Against Spinal-induced Hypotension in Elderly (NA)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |